In 2014, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, was approved to treat ovarian cancer for the first time (Pujade-Lauraine et al., 2014), and benefit from targeting angiogenesis, suppressing ovarian (and other) cancers from impeding their growth and spreads. This evidence concerns the gene VEGFA and ovarian cancer.